AI-generated from publicly available materials.Lord's Mark Industries Limited is advancing innovative breast cancer screening technology, preparing for clinical trials in multiple countries, including the USA and Europe. This initiative, in collaboration with C-MET, aims to enhance early detection using AI and thermal sensors, potentially revolutionizing access to screening.
The company has reported promising outcomes from earlier trials in India, where the technology demonstrated high accuracy in identifying cancerous cells. As they prepare for phase 2 trials set to begin in January 2027, Lord's Mark emphasizes the importance of regulatory approval to expand the technology's reach. The aim is to make this non-invasive, portable solution available in underserved areas, where traditional screening methods may be inaccessible.
With the global breast cancer diagnostics market projected to grow significantly, Lord’s Mark is positioning itself to meet this demand. The technology's ability to operate without radiation and with minimal infrastructure makes it a strong candidate for integration into national screening programs and insurance frameworks, enhancing affordability and accessibility for women.
This initiative could fundamentally change breast cancer screening practices, particularly in regions with limited healthcare resources. As the company pushes forward, successful trials and regulatory approvals will be critical in determining the technology's future impact on global health.